OtiTopic, Inc., founded in 2012, is a late-stage pharmaceutical company, with a track record of success in product drug delivery and drug device development. OtiTopic has changed the route of administration of a reference listed drug (RLD) and is on track to file a 505(b)(2) NDA for sale and marketing in the US.
Management of Suspected Heart Attack
A myocardial infarction (MI), commonly known as a heart attack, occurs every 40 seconds in the US. OtiTopic is committed to the development of a rapid therapy for the treatment of MI. OtiTopic has developed a dry powder inhalation treatment for MI that enters the bloodstream in less than two minutes.
Myocardial infarction occurs when an interruption in blood supply causes heart cell death from lack of oxygen and nutrients. Myocardial infarctions are typically caused by the blockage of a coronary artery by atherosclerotic plaque, a mass of cholesterol and white blood cells in the artery wall. OtiTopic has been working on the proprietary formulation since 2012 and is focused on bringing this therapy to market.
What we can offer
Advancing Asprihale® to Pivotal PK/PD Study02/26/2020
OtiTopic Advances ASPRIHALE® into Pivotal PK/PD Study01/02/2020
Otitopic Announces Results of Dose-Finding PK/PD Study for Asprihale® Dry Powder Inhalation of Aspirin for Acute Myocardial Infarction (MI)11/02/2019
Reducing Vascular Mortality in Patients With Suspected Acute MI04/08/2019
OtiTopic Pursues Additional New Indication for Dry Powder Inhalation of Aspirin as a Treatment for Non-Small-Cell Lung Cancer (NSCLC)03/25/2019
OtiTopic Moves towards Its Clinical Phase with Dry Powder Inhalation of Aspirin to Reduce the Risk of Vascular Mortality in Patients with Suspected Acute Myocardial Infarction02/27/2019
OtiTopic Granted Two Patents Covering its Dry Powder Inhaled Aspirin for the Treatment of Suspected Myocardial Infarction